(Q46909164)

26 December 2017

title

Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. (English)

1 reference

26 December 2017

1 reference

1 reference

Lakhanpaul M

1

1 reference

26 December 2017

Davies T

series ordinal

2

1 reference

26 December 2017

Allen BR

series ordinal

3

1 reference

26 December 2017

Schneider D

series ordinal

4

1 reference

26 December 2017

publication date

1 February 2006

1 reference

26 December 2017

published in

Experimental Dermatology

1 reference

26 December 2017

volume

15

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

page(s)

138-141

1 reference

26 December 2017

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Pimecrolimus: a review of its use in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Pimecrolimus -- an anti-inflammatory drug targeting the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00398.X

10.1111/J.1600-0625.2006.00398.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017